ENP Entropy reports 50% remission in Phase 2 psychedelic trial for binge eating disorder Entropy Neurodynamics says its Phase 2 trial of TRP-8803 delivered 50% remission in all treatment-resistant binge eating disorder patients. Seja Al Zaidi 4 days ago ASX News Healthcare Psychedelics
LGP Little Green Pharma jumps into distribution with acquisition Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to boost its distribution portfolio. Caroline Smith 20 Dec 2024 13:46 (AEDT) ASX News Healthcare Psychedelics
